<DOC>
	<DOCNO>NCT02709850</DOCNO>
	<brief_summary>The purpose ass safety , tolerability , pharmacokinetics , pharmacodynamics IONIS ANGPTL3-LRx ( ISIS 703802 ) give healthy volunteer subject elevate triglycerides subject familial hypercholesterolemia .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics IONIS ANGPTL3-LRx Healthy Volunteers With Elevated Triglycerides Subjects With Familial Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Riboflavin</mesh_term>
	<criteria>Inclusion Criteria All Cohorts : Must give write informed consent able comply study requirement Males females 18 65 year , inclusive , time informed consent BMI ≤ 35.0 kg/m2 Females must nonpregnant nonlactating , either surgically sterile postmenopausal . Males must surgically sterile , abstinent use acceptable contraceptive method Inclusion Criteria Cohorts A D Cohorts AA DD Only : Fasting TG &gt; 150 mg/dL Screening Fasting LDLC &gt; 70 mg/dL Screening Inclusion Criteria Cohort EE Only : Homozygous FH diagnosis fast LDLC ≥ 190 mg/dL ( 4.9 mmol/L ) Inclusion Criteria Cohort FF Only : Heterozygous FH diagnosis fast LDLC ≥ 160 mg/dL ( 4.1 mmol/L ) Inclusion Criteria Cohorts EE FF Only : Maximally tolerate stable LDLC lower agent ( stable least 12 week ) On stable lowfat diet Stable weight ( ± 4 kg ) ≥ 6 week prior screen Exclusion Criteria All Cohorts : Known history positive test HIV , HCV , HBV Treatment another Study Drug , biological agent , device within onemonth 5halflives screen Regular use alcohol within 6 month screen Use concomitant drug unless authorize Sponsor Medical Monitor Known contraindication and/or allergy heparin Smoking &gt; 10 cigarette day Considered unsuitable inclusion Principal Investigator Exclusion Criteria Cohorts EE FF : Myocardial infarction , percutaneous transluminal coronary intervention , coronary artery bypass graft surgery within 12 week prior screen , cerebrovascular accident within 24 week prior screen . Subjects adequately treat stable angina , per Investigator assessment , may include Congestive heart failure define NYHA Classes III IV T2DM HbA1c &gt; 8.0 % Prior treatment gene therapy Currently receive apheresis treatment last apheresis treatment within 8 week screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ANGPTL-3</keyword>
</DOC>